Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells

Biochem Pharmacol. 2011 Aug 15;82(4):418-25. doi: 10.1016/j.bcp.2011.05.013. Epub 2011 May 23.

Abstract

G protein-coupled receptors, the largest cell surface receptor family, have emerged as critical players in cell death and survival. High gene expression level of the G(q)-coupled P2Y(1) nucleotide receptor in PC-3 prostate cancer cells was demonstrated using real-time quantitative PCR and confirmed by Western blotting and confocal laser scanning microscopy. A selective P2Y(1) receptor agonist, the ADP analogue MRS2365, concentration-dependently induced intracellular calcium mobilization (EC(50) 5.28nM), which was diminished by P2Y(1) receptor-selective antagonist MRS2500. P2Y(1) receptor activation by MRS2365 induced apoptosis in assays of Caspase-3, LDH release, and annexin-V staining. The pro-apoptotic effect of MRS2365 was blocked by MRS2500, P2Y(1) siRNA, and an inhibitor of the MAP kinase pathway PD98059. MRS2365 significantly inhibited the proliferation of PC-3 cells, examined using a MTT assay. Thus, activation of the P2Y(1) receptor induced cell death and inhibited growth of human prostatic carcinoma PC-3 cells. Activation of the P2Y(1) receptor should be a novel and promising therapeutic strategy for prostate cancer.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects
  • Apoptosis / physiology*
  • Cell Line, Tumor
  • Cell Proliferation* / drug effects
  • Deoxyadenine Nucleotides / pharmacology
  • Deoxyadenine Nucleotides / therapeutic use
  • Gene Targeting / methods
  • Growth Inhibitors / pharmacology*
  • Humans
  • Male
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / metabolism*
  • Purinergic P2Y Receptor Agonists / pharmacology
  • Purinergic P2Y Receptor Antagonists / pharmacology
  • Receptors, Purinergic P2Y1 / genetics
  • Receptors, Purinergic P2Y1 / metabolism*

Substances

  • 2-iodo-N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate
  • Deoxyadenine Nucleotides
  • Growth Inhibitors
  • Purinergic P2Y Receptor Agonists
  • Purinergic P2Y Receptor Antagonists
  • Receptors, Purinergic P2Y1